Partnering Opportunities at IMBA
IMBA conducts cutting-edge basic research in various fields of molecular biology and biomedicine. In addition to scientific publications, we aim to translate our research results and proprietary technologies into tools to facilitate new discoveries and products to address currently unmet medical needs and improve human health.
IMBA is open for individual forms of technology transfer and eager to continuously expand our interactions with industrial partners. Since its foundation, IMBA has contributed to the incorporation of Austrian start-up companies, concluded numerous licensing agreements and entered into several research partnerships with biotech and pharma companies. A selection of most recent technology transfer activities can be found below.
The technologies and research projects that are currently available for licensing and/or partnering with industry or investors are listed here. For any further questions with respect to these partnering opportunities, please contact us directly.
Technologies & Projects available
Some of our partnering opportunities are commercialised in cooperation with Ascenion, a German technology transfer organisation exclusively dedicated to life sciences.
If you are interested in a research collaboration or licensing agreement with IMBA or an investment into an IMBA spin-off company, please contact us. If you are interested but haven't found a matching project, send us an e-mail and we will keep you updated on any new partnering opportunities!
Recent technology transfer activities:

a:head bio AG
Development of new drugs for the treatment of brain disorders based on human cerebral organoids.
Spin-Off, Licensing and Collaboration Agreement
Link to 1. press release
Link to 2. press release
Link to scientific publication (cerebral organoids model human brain development)
Link to scientific publication (fused cerebral organoids)

Lexogen
Commercialisation of SLAMSEQ - a high-sensitivity method for time-resolved measurement of newly synthesized and existing RNA in cultured cells (marketed since October 2017).
Licensing Agreement

Stem Cell Technologies
Commercialisation of a research reagent kit for establishment and maturation of human cerebral organoids based on IMBA’s proprietary cell culture protocol (marketed since July 2017).
Licensing Agreement
